The Relaxation Response Resiliency Enhancement Program in the Management of Chronic Refractory Temporomandibular Joint Disorder: Results from a Pilot Study-Reference-Cited by-同舟云学术

The Relaxation Response Resiliency Enhancement Program in the Management of Chronic Refractory Temporomandibular Joint Disorder: Results from a Pilot Study

Published:2013-08-24 Issue:3 Volume:21 Page:224-230
ISSN:1058-2452
Container-title:Journal of Musculoskeletal Pain
language:en
Short-container-title:Journal of Musculoskeletal Pain

Author:

Vranceanu Ana-Maria,Shaefer Jeffery R.,Saadi Ashkan Fahandej,Slawsby Ellen,Sarin Jaya,Scult Matthew,Benson Herbert,Denninger John W.

Publisher

Informa UK Limited

Subject

Rheumatology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10582452.2013.827289

Reference25 articles.

1. Cost-effectiveness of treatments for temporomandibular disorders

2. Management of masticatory myofascial pain

3. Treatment of mandibular dysfunction: the clinical usefulness of biofeedback in relation to splint therapy

4. An evaluation of electromyographic biofeedback in the treatment of myofascial pain-dysfunction syndrome

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of a virtual mind–body program on symptoms of depression and anxiety among international English‐speaking adults with neurofibromatosis;American Journal of Medical Genetics Part A;2024-02-06

2. Live Video Mind-Body Program for Patients With Knee Osteoarthritis, Comorbid Depression, and Obesity: Development and Feasibility Pilot Study;JMIR Formative Research;2022-04-27

3. Virtual Mind-Body Program for Obese Knee Osteoarthritis Patients with Comorbid Depression: Development and Feasibility Pilot (Preprint);2021-11-09

4. Getting Active Mindfully: Rationale and Case Illustration of a Group Mind-body and Activity Program for Chronic Pain;Journal of Clinical Psychology in Medical Settings;2021-01-19

5. Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial;General Hospital Psychiatry;2020-01